Zai Lab Announces the Appointment of Dr. Peter Huang as Chief Scientific Officer

SHANGHAI and CAMBRIDGE, Mass., Nov. 08, 2022 (GLOBE NEWSWIRE) -- Zai Lab Limited (NASDAQ: ZLAB; HKEX: 9688) a patient-focused, innovative, commercial-stage, global biopharmaceutical company, today announced the appointment of Dr. Peter Huang as its Chief Scientific Officer (CSO), effective immediately. Dr. Huang brings an extensive scientific background and strong leadership and research and development experience, including over 16 years working within the biopharmaceutical industry, to Zai Lab.

“We are excited to welcome Peter to our global leadership team,” said Dr. Samantha Du, Founder, Chairperson, and CEO of Zai Lab. “Peter has a strong track record in leading internal discovery research as well as external collaborations, and we look forward to driving innovation in drug research and development under his leadership.”

Dr. Huang will report to Josh Smiley, Chief Operating Officer of Zai Lab, and will be a key member of the Company’s executive committee. He will lead and oversee the Company’s discovery efforts and translational medicine.

“I look forward to joining Zai Lab and working with the incredible leadership and scientific teams to continue to grow and develop the company’s drug discovery and translational research programs,” said Dr. Huang. “Zai Lab has a number of exciting product candidates in its pipeline, and I am especially excited to oversee the development of this pipeline and to identify new product candidates that can help address unmet needs of patients in China and around the world.”